■ MicroPort^® MedBot and Robocath, a French Strategic Partner, have signed a final agreement to establish a joint venture of vascular interventional medical robots in China

■ After the establishment of the joint venture, the type of inspection and clinical trials will be launched immediately, prompting R-OneTM to be approved for listing in China as soon as possible and realizing the commercialization of its solutions

Shanghai, China --- MicroPort^® (Shanghai) Medbot Co., Ltd. (hereinafter referred to as "Microport^® Medbot") and Robocath, a French strategic partner (hereinafter referred to as “Robocath”), have signed a final agreement to establish a joint venture of vascular interventional medical robots in China MicroPort^® MedBot will hold 51% of the shares, while Robocath holds 49%.

Robocath was established in 2009, and its main business includes designing, developing and selling medical robot solutions for treating vascular diseases. R-One™ is the first robot system developed by Robocath, which aims to assist cardiovascular interventional physicians in stent implantation (angioplasty) by providing sophisticated technology to assist the existing surgical operations. R-One™ has an open architecture and is compatible with the mainstream interventional instruments and catheter rooms on the market. In a prospective, randomized and controlled preclinical trial, the technical success rate of R-One™ reached 100% and no major cardiovascular adverse event (MACE) has occurred, which fully proves its safety and effectiveness. R-One™ was CE certified in February 2019, and it is the first robot system in Europe to obtain CE certification in interventional cardiology. At present, R-One™ has been promoted to markets in Europe and Africa.

According to the agreement, the joint venture will launch the type of inspection and clinical trials right after its establishment, prompting R-One to be approved for listing in China as soon as possible to realize the commercial promotion of its solutions and set up a production base in China for the production and assembly of robot systems. Furthermore, both parties will jointly develop a new generation of remote-control technology using 5G network technology and jointly develop AI algorithms for robot-assisted platforms.

MicroPort^® MedBot was established in 2014. It is dedicated to providing integrated intelligent surgical solutions that can save patients' lives or improve their quality of life. Through years of R&D, innovation and industrial accumulation, it has developed into a medical robot company that has mastered the base technology of the whole chain of surgical robots. The Company has developed three flagship products: DFVision^® 3D Electronic Laparoscopic System, Toumai^® Laparoscopic Surgical Robot and Honghu ^®Honghu Orthopedic Surgical Robot (also known as "joint replacement surgery robot"), have all entered the "Green Path" of innovative medical devices in National Medical Products Administration. At present, the company's business covers five "Golden Racetracks": endoscopic, orthopedic, panvascular, natural lumen and percutaneous puncture fields.

The present cooperation has promoted Robocath's vascular interventional medical robot system to enter the Chinese market at an early date, and R-One™ has started preparations for type inspection and related technical cooperation. We are looking forward to establishing a stable and long-term cooperative relationship with MicroPort^® MedBot and jointly promoting the development of this product and technology in the Chinese market. --- Philippe Bencteux, Chairman and Founder of Robocath

Since the announcement of the establishment of strategic partnership between the two parties, we have made great progress in cooperation with Robocath. This has laid a solid foundation for the future development of vascular interventional medical robot market in China. We also look forward to bringing the world-class vascular interventional medical robots to the Chinese market in the future and benefiting more patients. --- Dr. He Chao, President of MicroPort^®MedBot